In this thirteenth video, the fifth from the afternoon breakout survivorship sessions, GRACE presents Exercise for Lung Cancer Patients, with Jeffrey Eagan DPT.
In this twelfth video from the Targeted Therapy in Lung Cancer Live Patient Forum Webcast series, GRACE presents the afternoon breakout sessions. The fourth video from these sessions is Dealing with Down Days, presented by Jeanice Hansen, MSW, LCSW, OSW-C.
In this eleventh video from the Targeted Therapies in Lung Cancer Patient Forum, the third from the afternoon breakout survivorship sessions, GRACE presents Chemo Brain, with Denise Damek, MD.
In this tenth video, the second from the afternoon breakout survivorship sessions, GRACE presents the Cancer Kitchen, with Lisa Wingrove, RD, CSO. Lisa is joined in this video by her lovely kitchen helper, Chris Draft.
In this ninth video from the webcast series, GRACE presents the breakout survivorship session - Bankruptcy and Workplace Discrimination with Patricia McMahon and Carlos Colon, AFC.
Sex is that one word that can mean and feel so different depending on the context of our lives. As young teenagers, the word may fill us with a sense...
2021 EN VIVO ONLINE Foro Español de Pacientes de Terapias Dirigidas 22 de julio de 2021 6:30 - 8:00 PM hora del este ¡Regístrate ahora! ¡La...
Applications are now open! 2021 Patient Education Ambassadors Program Online Information Form and Application available here! GRACE Patient Education...
Grace's 2nd Annual Spanish-Language Targeted Therapies Forum is coming up on Saturday, July 30! We are very excited to host this virtual event in...
Our Targeted Therapies Forum was Saturday 7/16/2022. The forum was/is packed full of excellent, understandable, and useful information from our...
I was dx Stage 4 squamous NSCLC with MET amplification mutation. I have been looking for 3 years for others that have squamous with any mutation. I'm...
Hello all! I am new to this forum, and although I have not been diagnosed with cancer, I did discover on a relatively recent CT scan that I have a 6mm...
Hi everyone, my father has been diagnosed with Stage IV NSCLC in 2013 with metastasis to the pelvic region. The biopsy at the time revealed tumor...
Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.
Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
Dr. Jack West, Swedish Cancer Institute, identifies the best choice for first-line chemotherapy for large-cell neuroendocrine histology.
Dr. Jack West, Swedish Cancer Institute, reviews the choices for a first-line chemotherapy regimen based on a squamous histology.
Dr. Jack West, Swedish Cancer Institute, addresses the issue of choosing a first-line chemotherapy regimen based on an adenocarcinoma histology.
Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.
Dr. Jack West, Swedish Cancer Institute, identifies the platinum-based chemotherapy doublet as the backbone of first-line treatment for the majority of NSCLC patients.
Dr. Ross Camidge, University of Colorado, addresses the question of whether to use a second generation ALK inhibitor as first line therapy or only after acquired resistance to crizotinib.
Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy.
Dr. Ross Camidge, University of Colorado, describes the second generation ALK-inhibitors which provide good options for ALK-positive NSCLC patients who have developed acquired resistance to crizotinib.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.